CA9hu-1 / CA9hu-2
Hypoxic Tumors (TNBC, ccRCC, NSCLC, Head & Neck, Mesothelioma)
Pre-clinicalActive
Key Facts
Indication
Hypoxic Tumors (TNBC, ccRCC, NSCLC, Head & Neck, Mesothelioma)
Phase
Pre-clinical
Status
Active
Company
About Mabpro
MABPRO is a private, European biotech focused on a novel CA IX-targeting immunotherapy platform for hypoxic tumors, including triple-negative breast cancer and renal cell carcinoma. The company integrates therapeutic antibody development with a sophisticated diagnostic and bioinformatics program for patient stratification, aligning with precision medicine. It has gained recognition through the Horizon Europe Seal of Excellence and positive EIC Accelerator evaluations, positioning it in the pre-clinical/early clinical development stage. MABPRO's strategy leverages a network of clinical and academic partners in Central Europe to advance its programs.
View full company profile